Uni Eropa - Slovak - EMA (European Medicines Agency)

ceva santé animale - benazepril hydrochloride, spironolactone - kardiovaskulÁrny systÉm - psy - na liečbu kongestívneho zlyhania srdca spôsobeného chronickým degeneratívnym ochorením chlopní u psov (s vhodnou diuretickou podporou).

Uni Eropa - Slovak - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Uni Eropa - Slovak - EMA (European Medicines Agency)

vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psycholeptiká, hypnotiká a sedatíva - psy - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.

Uni Eropa - Slovak - EMA (European Medicines Agency)

biomarin international limited - sapropterin dihydrochloride - phenylketonurias - iné alimentárny trakt a metabolizmus výrobky, - kuvan je indikovaný na liečbu hyperfenylalaninémie (hpa) u dospelých a pediatrických pacientov všetkých vekových skupín s fenylketonúriou (pku), u ktorých sa preukázalo, že reagujú na túto liečbu. kuvan je tiež indikovaný na liečbu hyperphenylalaninaemia (hpa) u dospelých a pediatrických pacientov všetkých vekových kategórií s tetrahydrobiopterin (bh4) nedostatok, ktorí sa ukázali byť vnímavý k takejto liečbe.

Uni Eropa - Slovak - EMA (European Medicines Agency)

gmp-orphan sa - trientine tetrahydrochloride - hepatolentikulárna degenerácia - iné alimentárny trakt a metabolizmus výrobky, - cuprior je indikovaný na liečbu wilsonova choroba u dospelých, dospievajúcich a detí ≥ 5 rokov trpiace neznášanlivosťou d-penicilamín terapia.

Uni Eropa - Slovak - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukémia, myeloidná, akútna - antineoplastické činidlá - liečba, akútna myeloidná leukémia.

Uni Eropa - Slovak - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastické činidlá - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Uni Eropa - Slovak - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioedémy, dedičné - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Uni Eropa - Slovak - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Uni Eropa - Slovak - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukémia, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.